Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies

Muhammad Hammad , Sadaf Fardoos , Khadija Shakoor

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004162

PDF (2904KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004162 DOI: 10.37349/ent.2026.1004162
Review
research-article
Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies
Author information +
History +
PDF (2904KB)

Abstract

Neurodegenerative and neurodevelopmental neurological disorders represent a growing global health burden, characterized by progressive neuronal dysfunction, cognitive decline, and impaired functional outcomes. Increasing evidence highlights neuroinflammation as a central pathophysiological mechanism linking mitochondrial dysfunction, oxidative stress, microbiota dysbiosis, and synaptic impairment across diverse neurological conditions. This narrative review was conducted using a structured literature search approach, incorporating major biomedical databases to enhance transparency and reproducibility. This review synthesizes contemporary evidence on mechanistic pathways underlying neuroinflammation-mediated neurodegeneration and critically evaluates emerging neuroprotective therapeutic strategies. Particular emphasis is placed on mitochondrial transfer approaches, novel circulating and imaging biomarkers, and integrative neurotechnological innovations such as artificial intelligence-driven neuroimaging analytics. While several therapeutic approaches demonstrate promise in preclinical models, most remain at early experimental or translational stages, with limited validation in large-scale human studies. Current findings suggest that targeting neuroimmune signaling cascades, restoring mitochondrial bioenergetics, and modulating gut-brain axis interactions may provide synergistic neuroprotective benefits. The review proposes a multidimensional precision-medicine framework incorporating biomarker-guided therapeutic selection and interdisciplinary care models. Future research priorities include longitudinal biomarker validation, randomized clinical trials of mitochondrial-based therapies, and integration of digital neurodiagnostic platforms to enhance early disease detection. Despite these advances, significant gaps remain in clinical translation, standardization of biomarkers, and long-term therapeutic safety, necessitating cautious interpretation of emerging evidence.

Keywords

neuroinflammation / neuroprotection / biomarkers / mitochondrial therapy / neurodegeneration / gut-brain axis

Cite this article

Download citation ▾
Muhammad Hammad, Sadaf Fardoos, Khadija Shakoor. Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004162 DOI:10.37349/ent.2026.1004162

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Tian J, Lu L, Wang Y, Wang Y, Tian S, Hu X, et al. Trends in Neglected Adolescent and Young Adults’ Neurological Diseases: A Systematic Analysis from the GBD Study 2021. Neuroepidemiology. 2025; 1-14.

[2]

Winkler AS, Gupta S, Patel V, Bhebhe A, Fleury A, Aukrust CG, et al. Global brain health-the time to act is now. Lancet Glob Health. 2024; 12: e735-6.

[3]

Rajendram R, Patel VB, Preedy VR. Neurological disorders in the context of the global burden of disease. In: Martin CR, Patel VB, Preedy VR, editors. Diet and Nutrition in Neurological Disorders. Academic Press; 2023. pp. 1-10.

[4]

Bomanji J, Fraioli F. Introduction to Brain Disorders. In: Fraioli F, editor. PET/CT in Brain Disorders. ; 2019. pp. 1-2.

[5]

McCullagh E, Brigstocke G, Donaldson N, Kalra L. Determinants of caregiving burden and quality of life in caregivers of stroke patients. Stroke. 2005; 36: 2181-6.

[6]

Agarwal SP. Synergy among the neuro-specialists. Neurol India. 2006; 54: 13-5.

[7]

Bain LJ, Jedrziewski K, Morrison-Bogorad M, Albert M, Cotman C, Hendrie H, et al. Healthy brain aging: a meeting report from the Sylvan M. Cohen Annual Retreat of the University of Pennsylvania Institute on Aging. Alzheimers Dement. 2008; 4: 443-6.

[8]

van Dijk G, van Heijningen S, Reijne AC, Nyakas C, van der Zee EA, Eisel UL. Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front Neurosci. 2015; 9: 173.

[9]

Townsend KL. One Nervous System: Critical Links Between Central and Peripheral Nervous System Health and Implications for Obesity and Diabetes. Diabetes. 2024; 73: 1967-75.

[10]

Martin J. Synaptic and Neuroglial Pathobiology in Acute and Chronic Neurological Disorders. In: de Vellis JS, editor. Neuroglia in the Aging Brain. Totowa: Humana Press; 2002. pp. 443-76.

[11]

Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010; 120: 277-86.

[12]

Alemán-Villa KM, Armienta-Rojas DA, Camberos-Barraza J, Rábago-Monzón ÁR, Camacho-Zamora A, Osuna-Ramos JF, et al. Neuroinflammation across the Spectrum of Neurodegenerative Diseases: Mechanisms and Therapeutic Frontiers. Neuroimmunomodulation. 2025; 32: 278-305.

[13]

Craft JM, Watterson DM, Eldik LJV. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets. 2005; 9: 887-900.

[14]

Moyse E, Krantic S, Djellouli N, Roger S, Angoulvant D, Debacq C, et al. Neuroinflammation: A Possible Link Between Chronic Vascular Disorders and Neurodegenerative Diseases. Front Aging Neurosci. 2022; 14: 827263.

[15]

Enciu A, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2016; 2016: 316495.

[16]

Chamani S, Bianconi V, Tasbandi A, Pirro M, Barreto GE, Jamialahmadi T, et al. Resolution of Inflammation in Neurodegenerative Diseases: The Role of Resolvins. Mediators Inflamm. 2016; 2016: 3267172.

[17]

Whittington RA, Planel E, Terrando N. Impaired Resolution of Inflammation in Alzheimer’s Disease: A Review. Front Immunol. 2017; 8: 1464.

[18]

Emre C, Hjorth E, Bharani K, Carroll S, Granholm A, Schultzberg M. Receptors for pro-resolving mediators are increased in Alzheimer’s disease brain. Brain Pathol. 2020; 30: 614-40.

[19]

Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol. 2005; 18: 315-21.

[20]

Schlotterose L, Cossais F, Lucius R, Hattermann K. Breaking the circulus vitiosus of neuroinflammation: Resveratrol attenuates the human glial cell response to cytokines. Biomed Pharmacother. 2023; 163: 114814.

[21]

Schubert P, Ferroni S. Pathological glial reactions in neurodegenerative disorders: prospects for future therapeutics. Expert Rev Neurother. 2003; 3: 279-87.

[22]

Casaril AM, Dantzer R, Bas-Orth C. Neuronal Mitochondrial Dysfunction and Bioenergetic Failure in Inflammation-Associated Depression. Front Neurosci. 2021; 15: 725547.

[23]

Dorothée G. Neuroinflammation in neurodegeneration: role in pathophysiology, therapeutic opportunities and clinical perspectives. J Neural Transm (Vienna). 2018; 125: 749-50.

[24]

Appel SH. Inflammation in Parkinson’s disease: cause or consequence? Mov Disord. 2012; 27: 1075-7.

[25]

Vieira S, Pinaya WH, Mechelli A. Using deep learning to investigate the neuroimaging correlates of psychiatric and neurological disorders: Methods and applications. Neurosci Biobehav Rev. 2017; 74: 58-75.

[26]

Díaz ML. Regenerative medicine: could Parkinson’s be the first neurodegenerative disease to be cured? Future Sci OA. 2019; 5: FSO418.

[27]

Graeber MB. Neuroinflammation: no rose by any other name. Brain Pathol. 2014; 24: 620-2.

[28]

Reale M, Brenner T, Greig NH, Inestrosa N, Paleacu D. Neuroinflammation, AD, and Dementia. Int J Alzheimers Dis. 2016; 2016: 974026.

[29]

Yang G, Xu X, Gao W, Wang X, Zhao Y, Xu Y. Microglia-orchestrated neuroinflammation and synaptic remodeling: roles of pro-inflammatory cytokines and receptors in neurodegeneration. Front Cell Neurosci. 2025; 19: 1700692.

[30]

Prieto GA, Tong L, Smith ED, Cotman CW. TNFα and IL-1β but not IL-18 Suppresses Hippocampal Long-Term Potentiation Directly at the Synapse. Neurochem Res. 2019; 44: 49-60.

[31]

Khatri N, Thakur M, Pareek V, Kumar S, Sharma S, Datusalia AK. Oxidative Stress: Major Threat in Traumatic Brain Injury. CNS Neurol Disord Drug Targets. 2018; 17: 689-95.

[32]

Mani S, Wasnik S, Shandilya C, Srivastava V, Khan S, Singh KK. Pathogenic synergy: dysfunctional mitochondria and neuroinflammation in neurodegenerative diseases associated with aging. Front Aging. 2025; 6: 1615764.

[33]

Peggion C, Calì T, Brini M. Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First? Antioxidants (Basel). 2024; 13: 240.

[34]

Cabré R, Jové M, Naudí A, Ayala V, Piñol-Ripoll G, Gil-Villar MP, et al. Specific Metabolomics Adaptations Define a Differential Regional Vulnerability in the Adult Human Cerebral Cortex. Front Mol Neurosci. 2016; 9: 138.

[35]

Torok J, Raj A. A joint model of network spread and selective vulnerability explains tau pathology spread in Alzheimer’s disease mouse models. Alzheimer’s Dement. 2023; 19: e065950.

[36]

Müller L, Benedetto SD, Müller V. Influence of biological sex on neuroinflammatory dynamics in the aging brain. Front Aging Neurosci. 2025; 17: 1670175.

[37]

Milatovic D, Zaja-Milatovic S, Brockett MM, Breyer RM, Aschner M, Montine TJ. Neuroinflammation and oxidative injury in developmental neurotoxicity. In: Gupta BC, editor. Reproductive and Developmental Toxicology. Academic Press; 2022. pp. 1129-40.

[38]

Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma. 2000; 17: 843-55.

[39]

Gorman AM, Ceccatelli S, Orrenius S. Role of mitochondria in neuronal apoptosis. Dev Neurosci. 2000; 22: 348-58.

[40]

Burté F, Carelli V, Chinnery PF, Yu-Wai-Man P. Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol. 2015; 11: 11-24.

[41]

Gao F, Zhang J. Mitochondrial quality control and neurodegenerative diseases. Neuronal Signal. 2018; 2:NS20180062.

[42]

Stamerra CA, Giosia PD, Giorgini P, Ferri C, Sukhorukov VN, Sahebkar A. Mitochondrial Dysfunction and Cardiovascular Disease: Pathophysiology and Emerging Therapies. Oxid Med Cell Longev. 2016; 2016: 9530007.

[43]

Kim S, Jung UJ, Kim SR. Role of Oxidative Stress in Blood-Brain Barrier Disruption and Neurodegenerative Diseases. Antioxidants (Basel). 2024; 13: 1462.

[44]

Riou A, Broeglin A, Grimm A. Mitochondrial transplantation in brain disorders: Achievements, methods, and challenges. Neurosci Biobehav Rev. 2025; 169: 105971.

[45]

Hayashida K, Takegawa R, Shoaib M, Aoki T, Choudhary RC, Kuschner CE, et al. Mitochondrial transplantation therapy for ischemia reperfusion injury: a systematic review of animal and human studies. J Transl Med. 2021; 19: 214.

[46]

Falk MJ, Decherney A, Kahn JP. Mitochondrial Replacement Techniques--Implications for the Clinical Community. N Engl J Med. 2016; 374: 1103-6.

[47]

Bodenstein DF, Siebiger G, Zhao Y, Clasky AJ, Mukkala AN, Beroncal EL, et al. Bridging the gap between in vitro and in vivo models: a way forward to clinical translation of mitochondrial transplantation in acute disease states. Stem Cell Res Ther. 2024; 15: 157.

[48]

Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des. 2014; 20: 5507-9.

[49]

Stefano GB, Kim C, Mantione K, Casares F, Kream RM. Targeting mitochondrial biogenesis for promoting health. Med Sci Monit. 2012; 18: SC1-3.

[50]

Zhou M, Zheng M, Liang S, Li M, Ma J, Zhang S, et al. Inherent potential of mitochondria-targeted interventions for chronic neurodegenerative diseases. Neural Regen Res. 2026; 21: 1409-27.

[51]

Neurology TL. Bringing forward the diagnosis of Alzheimer’s disease. Lancet Neurol. 2014; 13: 961.

[52]

Li T, Yang Q, Hu X, Han Y. Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage. Curr Neuropharmacol. 2022; 20: 713-37.

[53]

Gendron TF, Heckman MG, White LJ, Veire AM, Pedraza O, Burch AR, et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med. 2022; 3: 100607.

[54]

Daponte A, Koros C, Skarlis C, Siozios D, Rentzos M, Papageorgiou SG, et al. Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice. Int J Mol Sci. 2025; 26: 9739.

[55]

Galizzi G, Carlo MD. Mitochondrial DNA and Inflammation in Alzheimer’s Disease. Curr Issues Mol Biol. 2023; 45: 8586-606.

[56]

Shayota BJ. Biomarkers of mitochondrial disorders. Neurotherapeutics. 2024; 21: e00325.

[57]

Kantarci K, Jack CR. Predicting Progression of Alzheimer’s Disease With Magnetic Resonance. In: Broderick PA, Rahni DN, Kolodny EH, editors. Bioimaging in Neurodegeneration. Contemporary Neuroscience. Humana Press; 2005. pp. 95-105.

[58]

Schöll M. Advances in Alzheimer’s Disease. Brain Connect. 2023; 13: 266-8.

[59]

Wang R, Peng S, Zhu J, Xu Y, Wang M, Zhang L, et al. Innovations in Alzheimer’s disease diagnostic technologies: clinical prospects of novel biomarkers, multimodal integration, and non-invasive detection. Front Neurol. 2025; 16: 1651708.

[60]

Kwong AKL, Eeles AL, Spittle AJ. Early neurodevelopmental screening: Parent perspectives from the neonatal intensive care unit. Acta Paediatr. 2021; 110: 359-60.

[61]

Hasan A, Scuderi SA, Capra AP, Giosa D, Bonomo A, Ardizzone A, et al. An Updated and Comprehensive Review Exploring the Gut-Brain Axis in Neurodegenerative Disorders and Neurotraumas: Implications for Therapeutic Strategies. Brain Sci. 2025; 15: 654.

[62]

Bairamian D, Sha S, Rolhion N, Sokol H, Dorothée G, Lemere CA, et al. Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease. Mol Neurodegener. 2022; 17: 19.

[63]

Merra G, Placa GL, Covino M, Candelli M, Gasbarrini A, Franceschi F. The Impact of Microbiota on Neurological Disorders: Mechanisms and Therapeutic Implications. OBM Neurobiol. 2025; 09: 273.

[64]

Cryan JF, O’Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020; 19: 179-94.

[65]

Aderbal S, Ana M, Filho S, Selma S, Bandeira TL, Bandeira IM, et al. The brain-gut-microbiome axis. Int J Psychiatr Res. 2022; 5: 1-9.

[66]

Chen C, Wang G, Li D, Zhang F. Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol Biomed. 2025; 6: 64.

[67]

Quigley EMM, Shanahan F. Probiotics in Health Care: A Critical Appraisal. Annu Rev Med. 2025; 76: 129-41.

[68]

Tan EK, Wang JDJ, Pettersson S, Wang Q, Takahashi R, Poewe W, et al. Faecal microbiota transplant for Parkinson’s disease: promises and future directions. Brain. 2026; 149: 59-70.

[69]

Dai K, Ding L, Yang X, Wang S, Rong Z. Gut Microbiota and Neurodevelopment in Preterm Infants: Mechanistic Insights and Prospects for Clinical Translation. Microorganisms. 2025; 13: 2213.

[70]

Silva DF, Empadinhas N, Cardoso SM, Esteves AR. Neurodegenerative Microbially-Shaped Diseases: Oxidative Stress Meets Neuroinflammation. Antioxidants (Basel). 2022; 11: 2141.

[71]

Cummings JL, Tong G, Ballard C. Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. J Alzheimers Dis. 2019; 67: 779-94.

[72]

McKay KA, Kowalec K, Brinkman F, Finlay BB, Horwitz M, Manges AR, et al. From bugs to brains: The microbiome in neurological health. Mult Scler Relat Disord. 2017; 12: 1-3.

[73]

Schächtle MA, Rosshart SP. The Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research. Front Cell Neurosci. 2021; 15: 698172.

[74]

Kamini, Rani S. Artificial Intelligence and Machine Learning Models for Diagnosing Neurodegenerative Disorders. In: Koundal D, Jain DK, Guo Y, Ashour AS, Zaguia A, editors. Data Analysis for Neurodegenerative Disorders. ; 2023. pp. 15-48.

[75]

Ganjizadeh A, Wei Y, Erickson B. From Pixels to Prognosis: AI-Driven Insights into Neurodegenerative Diseases. MRAJ. 2024; 12: 1-20.

[76]

AbuAlrob MA, Mesraoua B. Harnessing artificial intelligence for the diagnosis and treatment of neurological emergencies: a comprehensive review of recent advances and future directions. Front Neurol. 2024; 15: 1485799.

[77]

Gracia-Tabuenca Z, Barbeau EB, Xia Y, Chai X. Predicting depression risk in early adolescence via multimodal brain imaging. Neuroimage Clin. 2024; 42: 103604.

[78]

Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019; 17: 195.

[79]

Peruzzo D, Castellani U, Perlini C, Bellani M, Marinelli V, Rambaldelli G, et al.; PICOS-Veneto Group. Classification of first-episode psychosis: a multi-modal multi-feature approach integrating structural and diffusion imaging. J Neural Transm (Vienna). 2015; 122: 897-905.

[80]

Lv Z, Guo J. Virtual Reality Neurorehabilitation. Int J Mental Health Promot. 2022; 24: 287-310.

[81]

Ku J, Kang YJ. Novel Virtual Reality Application in Field of Neurorehabilitation. Brain Neurorehabil. 2018; 11: e5.

[82]

Solares L, Llana T, García-Navarra S, Mendez M. Advances in Virtual Reality-Based Physical Rehabilitation for Neurodegenerative Diseases: A Systematic Review. Appl Sci. 2025; 15: 9903.

[83]

Bougea A. Mobile health technologies for the management of Parkinson’s disease. Expert Rev Neurother. 2025; 25: 1425-33.

[84]

Burridge JH, Lee ACW, Turk R, Stokes M, Whitall J, Vaidyanathan R, et al. Telehealth, Wearable Sensors, and the Internet: Will They Improve Stroke Outcomes Through Increased Intensity of Therapy, Motivation, and Adherence to Rehabilitation Programs? J Neurol Phys Ther. 2017; 41: S32-8.

[85]

Small SL. Precision neurology. Ageing Res Rev. 2025; 104: 102632.

[86]

Moonga J. Digital Biomarkers and Wearable Neurotechnologies: A Cost of Privacy and Security for Alzheimer’s Patients. Alzheimer’s Dement. 2023; 19: e065477.

[87]

Gkintoni E, Halkiopoulos C. Digital Twin Cognition: AI-Biomarker Integration in Biomimetic Neuropsychology. Biomimetics (Basel). 2025; 10: 640.

[88]

Mirzaei G, Gupta A, Adeli H. Data fusion of medical imaging in neurological disorders. Rev Neurosci. 2025; 37: 43-60.

[89]

Miyata K. Editorial: Role of assistive technologies to offer diagnosis, intervention and rehabilitation for individuals with neurological or neurodevelopmental disorder. Front Psychiatry. 2023; 14: 1159267.

[90]

Basu AP. Early intervention after perinatal stroke: opportunities and challenges. Dev Med Child Neurol. 2014; 56: 516-21.

[91]

Abbadessa G, Brigo F, Clerico M, Mercanti SD, Trojsi F, Tedeschi G, et al. Digital therapeutics in neurology. J Neurol. 2022; 269: 1209-24.

[92]

Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2012; 21: 1267-308.

[93]

Kim ME, Lee JS. Mechanisms and Emerging Regulators of Neuroinflammation: Exploring New Therapeutic Strategies for Neurological Disorders. Curr Issues Mol Biol. 2024; 47: 8.

[94]

Hanphanitphan S. Longitudinal Assessment of Biomarkers for Predicting Alzheimer’s Disease Progression: A Prospective Cohort Study in Thailand. Sriwijaya J Neurol. 2024; 2: 82-93.

[95]

Coulthard E, Hosseini AA. Blood biomarkers: ready for clinical practice? J Neurol Neurosurg Psychiatry. 2023; 94: 409-10.

[96]

Tariot P. Editorial: Blood-Based Biomarkers for Alzheimer’s Disease: Are We There Yet? J Prev Alzheimers Dis. 2022; 9: 565-6.

[97]

Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018; 90: e1212-21.

[98]

Koňaříková E, Marković A, Korandová Z, Houštěk J, Mráček T. Current progress in the therapeutic options for mitochondrial disorders. Physiol Res. 2020; 69: 967-94.

[99]

Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020; 19: 255-65.

[100]

Fang S, Yin Z, Cai Q, Li L, Zheng P, Chen L. Harnessing artificial intelligence for brain disease: advances in diagnosis, drug discovery, and closed-loop therapeutics. Front Neurol. 2025; 16: 1615523.

[101]

Boubga T, Bentaher A, Taous A, Ait Berri M, Boulahri T. Artificial Intelligence in Neurology: Current Applications and Future Prospects. IJISRT. 2024; 9: 104-10.

[102]

Corriveau-Lecavalier N, Mivalt F, Jones DT. Application of artificial intelligence frameworks in the clinical practice of neurology: recent advances and future directions. In: Chayakrit K, editor. Artificial Intelligence in Clinical Practice. Academic Press; 2024. pp. 169-76.

[103]

Liu L, Feigin V, Sacco RL, Koroshetz WJ. Promoting global collaboration for brain health research. BMJ. 2020; 371: m3753.

PDF (2904KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉